(Q36484979)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16716150%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

review article

1 reference

title

Rituximab in refractory autoimmune bullous diseases (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16716150%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16716150%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

author name string

Hunzelmann N

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16716150%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Zillikens D

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16716150%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Bröcker EB

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16716150%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Goebeler M

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16716150%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

publication date

1 July 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16716150%20AND%20SRC:MED&resulttype=core&format=json

Clinical and Experimental Dermatology

28 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16716150%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16716150%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16716150%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

page(s)

503-508

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16716150%20AND%20SRC:MED&resulttype=core&format=json

Rituximab in autoimmune diseases

28 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2006.02151.X

Mice carrying a CD20 gene disruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2006.02151.X

Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2006.02151.X

Treatment of childhood autoimmune haemolytic anaemia with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2006.02151.X

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2006.02151.X

The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2006.02151.X

T-cellular autoimmunity against desmogleins in pemphigus, an autoantibody-mediated bullous disorder of the skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2006.02151.X

Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2006.02151.X

Follicular non-Hodgkin's lymphoma with refractory paraneoplastic pemphigus: case report with review of novel treatment modalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2006.02151.X

Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2006.02151.X

Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2006.02151.X

Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2006.02151.X

Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2006.02151.X

B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2006.02151.X

Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2006.02151.X

Successful adjuvant treatment of recalcitrant epidermolysis bullosa acquisita with anti-CD20 antibody rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2006.02151.X

Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2006.02151.X

Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2006.02151.X

Rapid response of treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2006.02151.X

Long-standing remission of recalcitrant juvenile pemphigus vulgaris after adjuvant therapy with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2006.02151.X

Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2006.02151.X